LIVERPOOL (September 19, 2018) – The Liverpool School of Tropical Medicine (LSTM) and TB Alliance are collaborating to investigate novel combination drug therapies that could help the fight against multidrug-resistant tuberculosis (MDR-TB), following an award of £1 million from the Medical Research Council.

NEW YORK, NY (August 28, 2018)—TB Alliance has initiated a pivotal clinical trial, SimpliciTB (pronounced: sim-plis-i-tee-bee), that will evaluate whether a new four-drug regimen can treat most types of tuberculosis (TB) including multidrug-resistant TB (MDR-TB) more quickly and effectively than currently-available treatments. The first patients have been enrolled at the National Center for Tuberculosis and Lung Disease in Tbilisi, Georgia. SimpliciTB is expected to enroll 450 people with TB, including up to 150 with MDR-TB* across at least 26 centers in 10 countries in Africa, Asia, Europe and Latin America.

NEW YORK (7 February, 2018) — TB Alliance has announced the start of a clinical trial of a three-drug regimen to treat extensively drug resistant tuberculosis (XDR-TB)—one of the deadliest forms of tuberculosis (TB)—and those with pre-XDR-TB and multi-drug resident TB (MDR-TB) whose prior treatment has failed or who have not tolerated their treatment.

TB Alliance and Unitaid released a report, New pathways for childhood TB treatment: Lessons from the STEP-TB project, documenting how the STEP-TB project has reshaped the market for pediatric TB drugs by reducing barriers to entry, engaging in innovative industry collaboration to launch optimized products for children, and mobilizing strong demand. Since launching in 2015, these new medicines have begun to reach children around the world, setting a precedent for future action in the fight to end TB.

GUADALAJARA (10 October, 2017) — TBA-7371 and sutezolid entered phase 1 clinical trials, TB Alliance announced today. Both compounds have proceeded through early preclinical development and were granted “Investigative New Drug” status by the U.S. Food and Drug Administration. The phase 1 clinical trials are presently ongoing. 

EU leaders urge funding for new treatment and prevention tools against drug-resistant TB.

Agreement announced on World Tuberculosis Day revitalizes efforts to develop sutezolid as effective response to infectious disease killer.

USAID and TB Alliance will host an event, Innovating to End TB on 14 March 2017, 12:00 PM – 6:30 PM EDT in Washington, D.C., United States.

NEW YORK (21 December, 2016)—TB Alliance announced, based on positive results from the Phase 2b NC-005 trial, that it will now plan a Phase 3 study to test the BPaMZ (bedaquiline + pretomanid + moxifloxacin + pyrazinamide) regimen. In light of these results, where the BPaMZ regimen appears to be much more promising compared to the PaMZ (pretomanid + moxifloxacin + pyrazinamide) regimen, the STAND trial testing the PaMZ regimen will not be reopened to new patients. 

The government of Germany has announced its support for the development of new treatments to combat tuberculosis (TB). Germany’s Federal Ministry of Education and Research (BMBF) has committed EUR 10 million over five years to TB Alliance, facilitated by the KfW development bank. This grant is part of a slate of support intended to spur product development to fight neglected diseases.